Greenwich LifeSciences, Inc. filings document the reporting, governance, and public-company controls of a clinical-stage biopharmaceutical issuer developing GLSI-100 through the FLAMINGO-01 breast cancer recurrence program. Recent disclosures include a Form 12b-25 notice for a delayed annual report, proxy materials for the annual meeting, and Form 8-K reports on stockholder voting results.
The filing record also covers auditor appointment and change matters, board-election proposals, ratification of the independent registered public accounting firm, and internal-control disclosures referenced in accounting-firm transition materials.
Greenwich LifeSciences, Inc. notifies the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and expects to file the report by April 15, 2025, within the fifteen‑calendar‑day extension permitted under Rule 12b-25. The company attributes the delay to effort and expense required to complete the Annual Report.
The filing states research and development expense increased by approximately $4.6 million (about 35%) to $17.5 million for the year ended December 31, 2025 from $12.9 million in 2024, driven primarily by clinical expenses for the Phase III clinical trial; these amounts remain under review and may differ in the final Form 10-K.
Greenwich LifeSciences, Inc. director, CEO and CFO Snehal Patel, who is also a 10% owner, reported buying additional company stock. On January 13, 2026, he purchased 1,800 shares of common stock at a price of $29.83 per share. Following this open-market purchase, he beneficially owns 5,604,102 common shares, held in direct ownership.
Greenwich LifeSciences insider activity: Snehal Patel, who serves as CEO, CFO, director and a 10% owner of Greenwich LifeSciences, Inc., reported buying additional company stock. On 01/12/2026, he purchased 2,900 shares of common stock in an open market transaction coded as a "P" transaction at a price of $27.54 per share.
Following this purchase, Patel directly beneficially owned 5,602,302 shares of Greenwich LifeSciences common stock. The filing reflects direct ownership, with no indirect ownership reported in this transaction.
Greenwich LifeSciences, Inc. reported the results of its Annual Meeting of Stockholders held on December 18, 2025. A total of 8,944,615 shares of common stock were represented in person or by proxy, satisfying quorum requirements.
Stockholders elected all five director nominees — David McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, M.D., and Kenneth Hallock — to serve until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Each nominee received over 7.1 million votes “for,” with no votes “against,” and varying abstentions, alongside broker non-votes.
Stockholders also ratified the appointment of MaloneBailey LLP as the company’s independent registered public accounting firm for the fiscal year ended December 31, 2025, with 8,908,299 votes “for,” 31,459 “against,” and 4,857 “abstain.”
Greenwich LifeSciences, Inc. (GLSI) reported a Form 4 showing that CEO, CFO, director and 10% owner Snehal Patel received a grant of 100,000 stock options on 11/13/2025. These options have an exercise price of $8.2 per share and are exercisable into 100,000 shares of common stock, with an expiration date of 11/13/2035. Following this grant, Patel beneficially owns 2,347,462 derivative securities directly.
Greenwich LifeSciences (GLSI) reported Q3 2025 results with no revenue and a net loss of $4,151,845 (basic and diluted loss per share $0.30). For the nine months ended September 30, net loss was $11,435,485 as R&D rose to $3,521,576 in Q3 and $9,630,604 year to date, reflecting clinical spend and stock-based compensation; G&A reached $653,066 in Q3 and $1,872,323 year to date.
Cash was $3,806,978 at September 30. The company raised capital via its ATM, issuing 621,674 shares for gross proceeds of $6,492,994 (net $6,308,784) year to date, plus 59,962 shares for gross $631,362 (net $612,420) after quarter end. In September, remaining underwriter warrants were exercised for $145,000. Shares outstanding were 13,794,577 at September 30 and 13,854,539 as of October 28.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and reported material weaknesses in internal controls. The Phase III Flamingo‑01 trial of GLSI‑100 continues as the core operating focus.
Greenwich LifeSciences (GLSI) reported an insider open‑market purchase. Snehal Patel acquired 10,600 shares of common stock at $8.43 on 11/07/2025. After this transaction, his beneficial ownership stands at 5,583,502 shares, held directly.
Patel is the company’s CEO, CFO, a director, and a 10% owner. The report reflects one reporting person and lists the transaction in Table I; no derivative transactions are shown in Table II.
Greenwich LifeSciences (GLSI): Insider purchase reported. CEO, CFO and Director Snehal Patel, a 10% owner, bought 2,300 shares of common stock on 10/31/2025 at $9.26 per share. Following this transaction, he beneficially owned 5,572,902 shares, reported as direct ownership.
Greenwich LifeSciences will hold its Annual Meeting on December 18, 2025 at 9:00 a.m. local time in New York to elect five directors and ratify MaloneBailey LLP as independent auditor for fiscal 2025.
The record date is October 28, 2025, with 13,854,539 shares outstanding; a quorum requires 6,927,270 shares represented. Directors are elected by a plurality of votes cast, while auditor ratification requires a majority of shares present and entitled to vote.
Ownership is concentrated: CEO Snehal Patel beneficially owns 6,074,953 shares (41.11%); all directors and officers as a group hold 51.47%. 2024 CEO compensation totaled $6,241,685, including stock awards of $5,322,841. The Audit Committee dismissed RBSM and engaged MaloneBailey on July 19, 2025; 2024 audit fees were $64,000 and audit-related fees were $88,000.